XERIS BIOPHARMA HOLDINGS, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-12-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-03-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2025 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2023 was -$2.00K, a 128.57% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2022 was $7.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$9.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | -$9.00K derived: sum of 3 quarters · filed 2026-03-02 | $6.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$9.00K derived: sum of 2 quarters · filed 2026-03-02 | $6.00K derived: sum of 3 quarters · filed 2026-03-02 | $11.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.00K derived: sum of 2 quarters · filed 2026-03-02 | $11.00K derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2024-09-30 | $15.00K 10-Q · filed 2025-11-06 | $20.00K derived: sum of 2 quarters · filed 2025-11-06 | $9.00K 10-Q · filed 2025-11-06 | $35.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $5.00K 10-Q · filed 2025-08-07 | -$5.00K 10-Q · filed 2025-08-07 | $20.00K derived: sum of 3 quarters · filed 2026-03-02 | $48.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$10.00K 10-Q · filed 2025-05-08 | $15.00K derived: sum of 2 quarters · filed 2026-03-02 | $43.00K derived: sum of 3 quarters · filed 2026-03-02 | -$6.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $53.00K derived: sum of 2 quarters · filed 2026-03-02 | $4.00K derived: sum of 3 quarters · filed 2026-03-02 | -$2.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $28.00K 10-Q · filed 2024-11-08 | -$21.00K derived: sum of 2 quarters · filed 2024-11-08 | -$27.00K 10-Q · filed 2024-11-08 | -$15.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$49.00K 10-Q · filed 2024-08-08 | -$55.00K 10-Q · filed 2024-08-08 | -$43.00K derived: sum of 3 quarters · filed 2025-03-06 | -$27.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$6.00K 10-Q · filed 2024-05-09 | $6.00K derived: sum of 2 quarters · filed 2025-03-06 | $22.00K derived: sum of 3 quarters · filed 2025-03-06 | $36.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $28.00K derived: sum of 2 quarters · filed 2025-03-06 | $42.00K derived: sum of 3 quarters · filed 2025-03-06 | $7.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $16.00K 10-Q · filed 2023-11-09 | $30.00K derived: sum of 2 quarters · filed 2023-11-09 | -$5.00K 10-Q · filed 2023-11-09 | -$9.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $14.00K 10-Q · filed 2023-08-08 | -$21.00K 10-Q · filed 2023-08-08 | -$25.00K derived: sum of 3 quarters · filed 2024-03-06 | -$30.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$35.00K 10-Q · filed 2023-05-09 | -$39.00K derived: sum of 2 quarters · filed 2024-03-06 | -$44.00K derived: sum of 3 quarters · filed 2024-03-06 | -$56.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$9.00K derived: sum of 2 quarters · filed 2024-03-06 | -$21.00K derived: sum of 3 quarters · filed 2024-03-06 | -$38.00K 10-K · filed 2024-03-06 |
| 2021-09-30 | -$5.00K 10-Q · filed 2022-11-09 | -$17.00K derived: sum of 2 quarters · filed 2022-11-09 | -$34.00K 10-Q · filed 2022-11-09 | -$45.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$12.00K 10-Q · filed 2022-08-10 | -$29.00K 10-Q · filed 2022-08-10 | -$40.00K derived: sum of 3 quarters · filed 2022-08-10 | -$165.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$17.00K 10-Q · filed 2022-05-11 | -$28.00K derived: sum of 2 quarters · filed 2022-05-11 | -$153.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$136.00K derived: sum of 2 quarters · filed 2022-03-11 | -$10.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | -$125.00K 10-Q · filed 2021-11-10 | $1.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |